|
Philip George
Co-Investigator, ENABLE Trial Philip is a Consultant Haematologist at Wellington Hospital. He undertook Speciality Haematology training in the University Hospitals of Leicester, UK; which he completed in August 2022. In 2018 he took time out of clinical training to carry out a clinical research fellowship in Chimeric Antigen Receptor (CAR) T-cell therapy at the Malaghan Institute of Medical Research, Wellington. During his 3 year fellowship, he worked extensively on setting up the ENABLE trial: a Phase 1 anti-CD19 CAR T-Cell trial for patients with relapsed and refractory B-Cell Non Hodgkin Lymphoma. He was awarded a Masters of Clinical Research with distinction at the Victoria University of Wellington in August 2020. He continues to work as a Co-Investigator on the ENABLE trial alongside his duties as a Consultant Haematologist.
|
|
Anti-CD19 CAR T-Cell Therapy Clinical Research in New Zealand
Chimeric antigen receptor (CAR) T cell therapies directed against CD19 are a standard of care for relapsed or refractory (r/r) B-cell lymphomas in the US, Europe and Australia. We conducted the first CAR T-cell trial in NZ; a first-in-human phase 1 trial of WZTL-002, comprising autologous 1928T2z CAR T-cells (‘ENABLE’, NCT04049513) for patients with relapsed/refractory B-cell non-Hodgkin lymphomas. This talk discusses the science behind and rationale for CAR T-cell therapy. I will share some experiences gained from this trial, provisional results, and touch on potential future directions of CAR T-cell therapy in NZ.
Chimeric antigen receptor (CAR) T cell therapies directed against CD19 are a standard of care for relapsed or refractory (r/r) B-cell lymphomas in the US, Europe and Australia. We conducted the first CAR T-cell trial in NZ; a first-in-human phase 1 trial of WZTL-002, comprising autologous 1928T2z CAR T-cells (‘ENABLE’, NCT04049513) for patients with relapsed/refractory B-cell non-Hodgkin lymphomas. This talk discusses the science behind and rationale for CAR T-cell therapy. I will share some experiences gained from this trial, provisional results, and touch on potential future directions of CAR T-cell therapy in NZ.
